Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sentencing for FD&C Act violations

Executive Summary

The U.S. Sentencing Commission is considering amending sentencing guidelines applied to individuals and organizations convicted of criminal FD&C Act violations, and FDA's Office of Criminal Investigations appears to be pushing for stronger guidelines, according to Hyman, Phelps & McNamara's FDA law blog. The Commission's proposed priorities include treatment under the guidelines of offenses related to human growth hormone (of which there are currently none) and the Prescription Drug Marketing Act (for which the statutory maximum is 10 years). The commission has until May 1, 2008, to submit guideline amendments to Congress...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS049110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel